A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

Objective The natural history of nonradiographic axial spondyloarthritis (SpA) is incompletely characterized, and there are concerns that nonsteroidal antiinflammatory drugs provide inadequate disease control in patients with active disease. This study was undertaken to investigate the effects of ce...

Full description

Saved in:

Bibliographic Details
Published in:	Arthritis & rheumatology (Hoboken, N.J.) Vol. 71; no. 7; pp. 1101 - 1111
Main Authors:	Deodhar, Atul, Gensler, Lianne S., Kay, Jonathan, Maksymowych, Walter P., Haroon, Nigil, Landewé, Robert, Rudwaleit, Martin, Hall, Stephen, Bauer, Lars, Hoepken, Bengt, Peyrecave, Natasha, Kilgallen, Brian, Heijde, Désirée
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01.07.2019 John Wiley and Sons Inc
Subjects:	Active control Adult Ankylosing spondylitis Arthritis C-Reactive Protein - immunology Certolizumab Pegol - therapeutic use Disease control Double-Blind Method Female Humans Immunotherapy Inflammatory diseases Magnetic Resonance Imaging Male Middle Aged Monoclonal antibodies Nonsteroidal anti-inflammatory drugs Original Randomization Remission Rheumatic diseases Sacroiliitis - diagnostic imaging Spondylarthropathies - diagnostic imaging Spondylarthropathies - drug therapy Spondylarthropathies - immunology Spondylitis Spondyloarthritis TNF inhibitors Treatment Outcome Tumor Necrosis Factor Inhibitors - therapeutic use Tumor necrosis factor-α
ISSN:	2326-5191, 2326-5205, 2326-5205
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!